Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor (Q34628322)

3 August 2017

1 reference

title

Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor (English)

1 reference

3 August 2017

0 references

0 references

1 reference

1 reference

Craig T Hartrick

1

1 reference

PubMed ID

21476608

3 August 2017

Richard J Rozek

series ordinal

2

1 reference

3 August 2017

1 May 2011

1 reference

3 August 2017

1 reference

3 August 2017

25

1 reference

3 August 2017

359-370

1 reference

3 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.2165/11589080-000000000-00000

3 August 2017

0 references

cites work

Persistent postsurgical pain: risk factors and prevention

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Plasticity of NMDA receptor NR2B subunit in memory and chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

An overview of drug combination analysis with isobolograms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Synergism between paracetamol and nonsteroidal anti-inflammatory drugs in experimental acute pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Interactions between drugs and occupied receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

The spinal biology in humans and animals of pain states generated by persistent small afferent input

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Causalgia, pathological pain, and adrenergic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Interaction of morphine but not fentanyl with cerebral alpha2-adrenoceptors in alpha2-adrenoceptor knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Cannabinoid receptor-mediated antinociception with acetaminophen drug combinations in rats with neuropathic spinal cord injury pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

21 January 2018

Tapentadol Hydrochloride

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

In vitro and in vivo characterization of tapentadol metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Tapentadol immediate-release for acute pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled pha

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Tapentadol immediate release for the relief of moderate-to-severe acute pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11589080-000000000-00000

The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery

21 January 2018

1 reference

12 December 2020

Synergistic interaction between the two mechanisms of action of tapentadol in analgesia

1 reference

12 December 2020

Multimodal postoperative pain management

1 reference

12 December 2020

Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study

1 reference

12 December 2020

A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain

1 reference

12 December 2020

Dose conversion between tapentadol immediate and extended release for low back pain.

1 reference

12 December 2020

Evaluation of study discontinuations with tapentadol inmmediate release and oxycodone immediate release in patients with low back or osteoarthritis pain

1 reference

12 December 2020

A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects.

1 reference

12 December 2020

A double-blind, placebo-controlled study of dual-opioid treatment with the combination of morphine plus oxycodone in patients with acute postoperative pain

1 reference

12 December 2020

Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids

1 reference

12 December 2020

The hypoalgesic effect of tramadol in relation to CYP2D6*

1 reference

12 December 2020

The kappa opioid agonist U-50,488H antagonizes respiratory effects of mu opioid receptor agonists in conscious rats

1 reference

12 December 2020

Cortical representation of the sensory dimension of pain.

1 reference

12 December 2020

10.2165/11589080-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

21476608

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

21476608